1
|
Rao Q, Yang Y, Wang S, Zhu H, Jin L, Zhang J, Liu M. Optimal dosing regimen of biapenem based on population pharmacokinetic/pharmacodynamic modeling and Monte Carlo simulation in Febrile Neutropenic Patients with Hematologic Malignancies. Int J Antimicrob Agents 2023:106841. [PMID: 37160241 DOI: 10.1016/j.ijantimicag.2023.106841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 04/18/2023] [Accepted: 05/03/2023] [Indexed: 05/11/2023]
Abstract
In the current study, a population pharmacokinetic (PPK) model was developed for biapenem in patients with febrile neutropenia (FN) who have hematological malignancies. Through Monte Carlo simulation, optimal administration regimens were suggested based on the developed PPK model. In a perspective, single-center, open-label study, 174 plasma samples from 120 Chinese patients with FN having hematological malignancies were analyzed by chromatography, and PK parameters were analyzed by NONMEM®. The drug clearance process was influenced by crucial covariates, namely creatinine clearance rate (CLCR) and concomitant posaconazole (POS). The ultimate PPK model was as follows: CL (L/h) = 29.81 × (CLCR/121.38)0.806 × (1-POS × 0.297); V(L) = 114. For the target of ≥40% fT > minimum inhibitory concentration (MIC) (the duration that the plasma level exceeds the MIC of the causative pathogen) and achieving the probability of target attainment ≥90%, the PK/pharmacodynamic breakpoint was 2 mg/L for the 2.4 g/d-dosing regimen consisting of 600 mg q6h and 800 mg q8h. The breakpoint was 1 mg/L for the 1.2 g/d-dosing regimen consisting of 300 mg q6h and 600 mg q12h. Empirical therapy would benefit from utilizing higher dosages and extended infusion durations. Therefore, it is suggested that patients with symptoms that are strongly suspected of Pseudomonas aeruginosa or Acinetobacter baumannii infections may be suitable for combined treatment with other antibacterial drugs.
Collapse
Affiliation(s)
- Qi Rao
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China
| | - Yonggong Yang
- Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
| | - Siliang Wang
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
| | - Huaijun Zhu
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
| | - Lu Jin
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
| | - Jinping Zhang
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
| | - Mengying Liu
- Department of Pharmacy, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing 210008, China; Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
| |
Collapse
|